BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB (publ) (BRCTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.002x
Based on the latest financial reports, BioArctic AB (publ) (BRCTF) has a cash flow conversion efficiency ratio of -0.002x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.36 Million) by net assets ($1.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioArctic AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioArctic AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioArctic AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aehr Test Systems
NASDAQ:AEHR
|
-0.011x |
|
Guangdong Meiyan Jixiang Hydropower Co Ltd
SHG:600868
|
0.026x |
|
Chongqing Chuanyi Automation Co Ltd
SHG:603100
|
0.026x |
|
SAI LIFE SCIENCES LTD
NSE:SAILIFE
|
N/A |
|
WT Microelectronics Co. Ltd. Pfd.
TW:3036A
|
0.075x |
|
Sundram Fasteners Limited
NSE:SUNDRMFAST
|
0.098x |
|
Feng Tay Enterprises Co Ltd
TW:9910
|
0.173x |
|
Sixt SE
PINK:SIXGF
|
0.081x |
Annual Cash Flow Conversion Efficiency for BioArctic AB (publ) (2015–2024)
The table below shows the annual cash flow conversion efficiency of BioArctic AB (publ) from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $894.94 Million | $-316.33 Million | -0.353x | -219.45% |
| 2023-12-31 | $1.05 Billion | $309.69 Million | 0.296x | +835.38% |
| 2022-12-31 | $786.24 Million | $-31.64 Million | -0.040x | +77.41% |
| 2021-12-31 | $788.68 Million | $-140.46 Million | -0.178x | -74.98% |
| 2020-12-31 | $907.30 Million | $-92.34 Million | -0.102x | -130.32% |
| 2019-12-31 | $974.50 Million | $327.17 Million | 0.336x | +270.79% |
| 2018-12-31 | $1.02 Billion | $-200.06 Million | -0.197x | +7.60% |
| 2017-12-31 | $636.13 Million | $-135.33 Million | -0.213x | -101.91% |
| 2016-12-31 | $60.76 Million | $675.13 Million | 11.111x | +7421.42% |
| 2015-12-31 | $108.28 Million | $-16.43 Million | -0.152x | -- |